## Edgar Filing: NEOTHERAPEUTICS INC - Form 8-K

NEOTHERAPEUTICS INC Form 8-K May 07, 2002

> UNITED STATES SECURITIES AND EXCHANGE COMMISSION

> > Washington, D.C. 20549

\_\_\_\_\_

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES AND EXCHANGE ACT OF 1934

May 7, 2002 Date of Report (Date of earliest event reported)

\_\_\_\_\_

NEOTHERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

DELAWARE

000-28782

93-0979187

(State or other Jurisdiction (Commission File Number) of Incorporation)

(IRS Employer Identification Number)

157 TECHNOLOGY DRIVE IRVINE, CALIFORNIA (Address of principal executive offices)

92618 (ZIP CODE)

(949) 788-6700 (Registrant's telephone number, including area code)

N/A (Former Name or Former Address, if Changed Since Last Report)

ITEM 5. OTHER EVENTS.

On May 7, 2002, NeoTherapeutics, Inc. issued a news release announcing that the Company has shifted its strategic focus to out-licensing of neurology drug candidates and internal development of oncology drugs and will include strategic and restructuring changes to reduce the Company's monthly expenses. The text of the press release is set forth in Exhibit 99.1 attached to this report and incorporated herein by this reference.

## Edgar Filing: NEOTHERAPEUTICS INC - Form 8-K

ITEM 7. EXHIBITS

Exhibits:

99.1 Press Release dated May 7, 2002.

## SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

NEOTHERAPEUTICS, INC.

Date: May 7, 2002

By: /s/Samuel Gulko Name: Samuel Gulko

Title: Senior Vice President Finance, Chief Financial Officer, Secretary and Treasurer

Exhibit Number Document Description

99.1 Press Release dated May 7, 2002.